Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Journal of Clinical Oncology (2017)
  • Steven E. Coutre, Stanford University
  • Richard R. Furman, NewYork–Presbyterian Hospital
  • Jeff Porter Sharman, Cancer Institute
  • Bruce D. Cheson, Georgetown University
  • John M. Pagel, Cancer Institute
  • Peter Hillmen, St James's University Hospital
  • Jacqueline Claudia Barrientos, Hofstra University
  • Andrew David Zelenetz, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, University of California, San Diego
  • Ian Flinn, Sarah Cannon Research Institute
  • Paolo Ghia, Vita-Salute San Raffaele University
  • Herbert Aaron Eradat, University of California, Los Angeles
  • Thomas J. Ervin, Harvard University
  • Nicole Lamanna, Columbia University Medical Center
  • Bertrand Coiffier, Claude Bernard University Lyon 1
  • Andrew Pettitt, University of Liverpool
  • Yeonhee Kim
  • Thomas Michael Jahn, Children's Hospital Los Angeles
  • Susan Mary O'Brien, Queen Mary University of London
  • Michael J. Hallek, University of Cologne
Link
Disciplines
Publication Date
January 31, 2017
Citation Information
Steven E. Coutre, Richard R. Furman, Jeff Porter Sharman, Bruce D. Cheson, et al.. "Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/john-pagel/16/